Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uriexo Double Action
- Development stage
- Unknown
- Lead developer
- Tyros Biopharma
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Uriexo Double Action is a Health Canada-licensed natural health product formulated to prevent recurrent urinary tract infections (UTIs). It is a non-antibiotic, dual-action oral supplement that combines D-mannose and cranberry-derived proanthocyanidins (PACs). The combination works synergistically to inhibit the adhesion of uropathogenic *Escherichia coli* (UPEC) to the urinary tract lining. Specifically, D-mannose acts as a molecular decoy that binds to type 1 fimbriae (FimH) on the bacterial surface, while cranberry PACs bind to P-fimbriae (PapG). By blocking these two distinct bacterial anchoring sites, Uriexo Double Action prevents bacteria from adhering to the bladder wall and urothelium, allowing them to be naturally flushed out during urination.
- Brand names
- Uriexo Double Action
- Other names
- cranberry extract + D-mannoseD-mannose + cranberry extract
02
Targets
FimH (Type 1 fimbrial adhesin)Sphingolipid (Sphingolipid metabolism)UPK1A (Uroplakin-1a)PapG (PapG adhesin)
Beyond the preview
Go deeper on Uriexo Double Action.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Uriexo Double Action.